Human Study on Serum Neurofilament Light Chain (sNfL) in Multiple Sclerosis
The research indicates that serum neurofilament light chain (sNfL) is a biomarker associated with neuroaxonal injury in multiple sclerosis. It is linked to inflammatory disease activity, treatment response, and potential clinical outcomes. However, discrepancies exist regarding its clinical application in MS management.
- Tags
- #Biomarkers
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Moderate
- Outcome
- Not reported
Why it matters
Understanding the role of sNfL could enhance decision-making in managing MS, potentially leading to better patient outcomes based on neuroaxonal injury assessment.
What this does not prove
While sNfL may inform management strategies, current evidence does not prove that using this information directly improves patient outcomes, and definitive benefits are still under evaluation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-06
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- serum neurofilament light chain (sNfL)
- Safety
- Not reported
Original sources
- Primary evidenceBeyond biomarker validation: defining when serum neurofilament light chain should influence management in multiple sclerosis. ↗DOI: 10.3389/fimmu.2026.1979820
Supporting passages (11)
study phasePublication types: Journal Article; Review
study designPublication types: Journal Article; Review
subjectsMeSH terms: Humans; Biomarkers; Neurofilament Proteins; Multiple Sclerosis; Disease Management
speciesMeSH terms: Humans; Biomarkers; Neurofilament Proteins; Multiple Sclerosis; Disease Management
peer reviewedJournal: Frontiers in immunology
publication datePublication date: 2026-10-06
biomarkersAs a downstream marker of tissue injury rather than a direct readout of a specific immune pathway, its increasing availability raises a more demanding question: when does sNfL provide enough additional information to improve management of an individual patient?
findingsCurrent evidence best supports its role as a decision-support biomarker: unexpected or persistent abnormalities may justify verification, closer surveillance, or targeted reassessment, whereas normal values cannot reliably exclude clinically relevant MS biology, including relapse-independent disability accumulation.
limitationsEvidence that sNfL predicts outcomes or influences intended management does not establish that acting on this information improves patient outcomes.
peer reviewedPublication types: Journal Article; Review
research categoriesMeSH terms: Humans; Biomarkers; Neurofilament Proteins; Multiple Sclerosis; Disease Management
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.